0
0
January 18, 2026
SYDNEY — Researchers have uncovered a potential breakthrough in the treatment of one of the most aggressive and traditionally untreatable forms of childhood brain cancer. A study led by the Children’s Cancer Institute and the University of New South Wales (UNSW) has demonstrated that a “double-hit” combination therapy can effectively shut down the growth of diffuse midline gliomas (DMGs) in laboratory settings. By simultaneously targeting two specific proteins that allow cancer cells to multiply, the combined treatment not only slowed tumor progression in animal models but also appeared to “unmask” the cancer cells, potentially making them more vulnerable to the body’s own immune system.
The Challenge of a “Genetic Hurricane”
Diffuse midline gliomas, which include the devastating Diffuse Intrinsic Pontine Glioma (DIPG), represent a significant challenge in pediatric oncology. These tumors are located in the brainstem—the area controlling vital functions like breathing and heart rate—making surgical removal impossible. Currently, the prognosis remains grim; children diagnosed with DIPG typically survive only 12 months post-diagnosis.
The primary obstacle in treating DMGs is their genetic complexity. Unlike some cancers driven by a single mutation, DMGs are characterized by a “genetic hurricane,” where thousands of genes are switched on simultaneously, driving rapid and relentless growth.
“It has proven extremely difficult to find a way to switch them all off,” explains UNSW Conjoint Professor David Ziegler, a senior author of the study.
Targeting the “Engine Room” of Cancer
The Australian research team, published recently in Science Translational Medicine, shifted their focus toward the “engine room” of the cancer cell: the transcription process. Transcription is the method cells use to read genetic instructions and turn them into proteins.
In DMG cells, two specific proteins—FACT and BET—are found at abnormally high levels. These proteins act as facilitators, ensuring the transcription machinery can move quickly through the cancer’s DNA to keep the tumor growing.
While drugs designed to block either FACT or BET have existed for years, they have shown limited success when used individually. The cancer cells often find “workarounds” to survive. However, the researchers discovered that when these two inhibitors are used in tandem, the results change dramatically.
“We recognize that no single drug treatment is able to eradicate the most aggressive of brain cancers on its own,” said Conjoint Associate Professor Maria Tsoli from UNSW.
In laboratory experiments on cell cultures, the combination therapy didn’t just slow the cancer; it caused the cells to die. When tested in mice with DMG, the dual-drug approach significantly slowed tumor growth and extended the subjects’ survival time compared to single-drug treatments or placebos.
Priming the Immune System
Perhaps the most surprising finding was the treatment’s effect on the “visibility” of the tumor. Typically, brain cancers are “cold,” meaning they are effectively invisible to the immune system.
The study found that the combination of FACT and BET inhibitors activated signals linked to the immune system within the tumor cells. By disrupting the cancer’s internal wiring, the drugs essentially “flagged” the cells for destruction.
This discovery opens the door for a “triple-threat” approach. The researchers suggest that this drug combination could be used to prime the tumor before administering immunotherapy, such as CAR T-cell therapy, which engineers a patient’s own immune cells to attack the cancer.
A Balanced Perspective: From Lab to Bedside
While the results are a cause for optimism, medical experts urge caution. Results in laboratory models and mice do not always translate perfectly to human patients. The “blood-brain barrier”—a protective shield that prevents many drugs from entering the brain—remains a significant hurdle for any systemic treatment.
“Translating laboratory success into clinical reality is a multi-step process,” says Dr. Elena Rossi, a pediatric oncologist not involved in the study. “We need to ensure that this combination can reach the tumor in high enough concentrations without causing prohibitive toxicity in a developing child’s brain.”
Furthermore, the study focused on the genetic “shut-off” mechanism. While thousands of genes were deactivated, cancer is notoriously adaptive. Long-term studies will be required to determine if the tumors can develop resistance to this specific dual-protein blockade.
Practical Implications for Families
For families currently facing a DMG or DIPG diagnosis, this research offers a roadmap for future clinical trials rather than an immediate cure. Both FACT and BET inhibitors are currently in various stages of separate clinical trials for other adult and pediatric cancers. This means the safety profiles are already being established, which could potentially accelerate the timeline for a combined human trial.
Parents are encouraged to speak with their oncology teams about emerging “basket trials” or “platform trials” that allow for the testing of multiple drug combinations based on the latest molecular research.
The Road Ahead
The Australian team is now looking toward the next phase of research, which involves refining the delivery methods for these drugs and exploring the synergy with CAR T-cell therapies.
“Our goal is to turn a fatal diagnosis into a manageable or curable condition,” says Professor Ziegler. “By attacking the cancer from multiple angles simultaneously, we are finally starting to see the ‘off switch’ for these tumors.”
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://tennews.in/combining-two-medicines-may-help-treat-childhood-brain-cancer-study/
